keyword
MENU ▼
Read by QxMD icon Read
search

ius levonorgestrel

keyword
https://www.readbyqxmd.com/read/28921518/high-birth-rates-despite-easy-access-to-contraception-and-abortion-a-cross-sectional-study
#1
Helena Hognert, Finn Egil Skjeldestad, Kristina Gemzell-Danielsson, Oskari Heikinheimo, Ian Milsom, Øjvind Lidegaard, Ingela Lindh
INTRODUCTION: The aim was to describe and compare contraceptive use, fertility, birth and abortion rates in the Nordic countries. MATERIAL AND METHODS: National data on births, abortions, fertility rate (1975-2013), redeemed prescriptions of hormonal contraceptives and sales figures of copper intrauterine devices (2008-2013) among women 15-49 years of age in the Nordic countries were collected and analysed. RESULTS: Use of hormonal contraceptives and copper intrauterine devices varied between 31-44%...
September 16, 2017: Acta Obstetricia et Gynecologica Scandinavica
https://www.readbyqxmd.com/read/28915701/comparison-among-fertility-sparing-therapies-for-well-differentiated-early-stage-endometrial-carcinoma-and-complex-atypical-hyperplasia
#2
REVIEW
Qing Zhang, Gonghua Qi, Margaux J Kanis, Ruifen Dong, Baoxia Cui, Xingsheng Yang, Beihua Kong
OBJECTIVE: To compare fertility-sparing therapies including oral progestogens, hysteroscopic resection (HR), and the levonorgestrel- releasing intrauterine system (LNG-IUS) in achieving disease regression, recurrence and live birth rate in well differentiate early-stage endometrial carcinoma (eEC) and complex atypical hyperplasia(CAH). STUDY DESIGN: This was a meta-analysis of previous studies focus on the fertility-sparing therapy for well differentiate early-stage endometrial carcinoma (eEC) and complex atypical hyperplasia (CAH)...
August 22, 2017: Oncotarget
https://www.readbyqxmd.com/read/28913650/does-levonorgestrel-releasing-intrauterine-system-increase-breast-cancer-risk-in-peri-menopausal-women-an-hmo-perspective
#3
Nava Siegelmann-Danieli, Itzhak Katzir, Janet Vesterman Landes, Yaakov Segal, Rachel Bachar, Hadas Rotem Rabinovich, Martin Bialik, Joseph Azuri, Avi Porath, Yossef Lomnicky
PURPOSE: To evaluate the association between levonorgestrel-releasing intrauterine system (LNG-IUS) use and breast cancer (BC) risk. METHODS: A cohort of all Maccabi Healthcare Services (MHS) female members aged 40-50 years between 1/2003 and 12/2013 was used to identify LNG-IUS users as "cases," and 2 age-matched non-users as "controls." Exclusion criteria included: prior BC diagnosis, prior (5 years pre-study) and subsequent treatment with other female hormones or prophylactic tamoxifen...
September 14, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28892980/evaluating-the-efficacy-of-levonorgestrel-intrauterine-system-and-danazol-for-relief-of-postoperative-pain-in-endometriosis
#4
Ashima Taneja, Satinder Kaur, R K Soni, Bhanupriya, Jaspreet Kaur, Laveen Singla
INTRODUCTION: Endometriosis is an oestrogen-dependent disorder, manifests during reproductive years and is associated with pain and infertility. There is considerable debate about the effectiveness of various interventions for pain relief. AIM: To evaluate the efficacy of Levonorgestrel Intrauterine System (LNG-IUS) and Danazol in postoperative pain relief for patients with endometriosis. MATERIALS AND METHODS: Hundred patients with diagnosis of endometriosis, who were treated laparoscopically, entered the study to receive either danazol (600 mg once daily) or LNG-IUS (inserted during immediate post operative period) postsurgery, for pain relief...
July 2017: Journal of Clinical and Diagnostic Research: JCDR
https://www.readbyqxmd.com/read/28867443/association-of-hormonal-contraception-with-depression-in-the-postpartum-period
#5
Timothy A Roberts, Shana Hansen
OBJECTIVES: Studies have demonstrated an association between hormonal contraception use with subsequent depression and antidepressant use. This association has not been assessed among postpartum women. STUDY DESIGN: This study is a secondary analysis of insurance records from 75,528 postpartum women enrolled in the US military medical system, who delivered between October 2012 and September 2014. Our analyses excluded women who used antidepressants or had a diagnosis of depression in the 24months prior to delivery...
August 31, 2017: Contraception
https://www.readbyqxmd.com/read/28844878/overcoming-barriers-to-levonorgestrel-releasing-intrauterine-system-placement-an-evaluation-of-placement-of-lng-ius-8-using-the-modified-evoinserter%C3%A2-in-a-majority-nulliparous-population
#6
Kristina Gemzell-Danielsson, Dan Apter, Eeva Lukkari-Lax, Katrin Roth, Marco Serrani
OBJECTIVES: To report placement success rate, and ease and pain associated with placement, of the levonorgestrel-releasing intrauterine system (LNG-IUS) 8 using the modified EvoInserter® placement device. STUDY DESIGN: This was a pooled analysis using data from three previously reported Phase III studies in nulliparous (83.3%) or parous (16.7%) women aged 12-35years (N=965). LNG-IUS 8 was placed using the modified Evolnserter®. The main outcomes assessed were placement success, ease of placement as reported by healthcare professionals (HCPs), pain at placement as reported by participants, and assessment of the EvoInserter® placement device by HCPs...
August 24, 2017: Contraception
https://www.readbyqxmd.com/read/28833891/relationship-between-user-satisfaction-with-the-levonorgestrel-releasing-intrauterine-system-and-bleeding-patterns
#7
Nelsilene M Carvalho, Victoria Chou, Waleska Modesto, Deborah Margatho, Elaine A L Garcia, Luis Bahamondes
AIM: Satisfaction with a contraceptive method constitutes an important factor in its acceptance and long-term use. The objective of this study was to assess the relationship between user satisfaction with the 20-μg/day levonorgestrel-releasing intrauterine system (LNG-IUS) and the bleeding patterns reported at two different time-points during follow-up. METHODS: A total of 251 LNG-IUS users aged 18-45 years were invited to answer a questionnaire on their return to the clinic for a routine follow-up visit and again 1 year later...
August 17, 2017: Journal of Obstetrics and Gynaecology Research
https://www.readbyqxmd.com/read/28826801/postplacental-intrauterine-device-expulsion-by-12-weeks-a%C3%A2-prospective-cohort-study
#8
Lisa M Goldthwaite, Jeanelle Sheeder, Jennifer Hyer, Kristina Tocce, Stephanie B Teal
BACKGROUND: An intrauterine device placed immediately following a delivery can serve as an effective and safe contraceptive strategy in the postpartum period. There is limited evidence that the levonorgestrel intrauterine system may have a higher rate of expulsion compared to the copper intrauterine device; however, rates of expulsion for these 2 intrauterine device types have not been compared directly. OBJECTIVE: We sought to compare expulsion rates by 12 weeks' postpartum for the levonorgestrel intrauterine system and copper intrauterine device...
August 19, 2017: American Journal of Obstetrics and Gynecology
https://www.readbyqxmd.com/read/28796898/comparison-of-the-levonorgestrel-releasing-intrauterine-system-hysterectomy-and-endometrial-ablation-for-heavy-menstrual-bleeding-in-a-decision-analysis-model
#9
REVIEW
Michelle Louie, Jennifer Spencer, Stephanie Wheeler, Victoria Ellis, Tarek Toubia, Lauren D Schiff, Matthew T Siedhoff, Janelle K Moulder
BACKGROUND: A better understanding of the relative risks and benefits of common treatment options for abnormal uterine bleeding (AUB) can help providers and patients to make balanced, evidence-based decisions. OBJECTIVES: To provide comparative estimates of clinical outcomes after placement of levonorgestrel-releasing intrauterine system (LNG-IUS), ablation, or hysterectomy for AUB. SEARCH STRATEGY: A PubMED search was done using combinations of search terms related to abnormal uterine bleeding, LNG-IUS, hysterectomy, endometrial ablation, cost-benefit analysis, cost-effectiveness, and quality-adjusted life years...
August 10, 2017: International Journal of Gynaecology and Obstetrics
https://www.readbyqxmd.com/read/28780893/abnormal-uterine-bleeding-in-perimenopause
#10
S R Goldstein, M A Lumsden
Abnormal uterine bleeding is one of the commonest presenting complaints encountered in a gynecologist's office or primary-care setting. The wider availability of diagnostic tools has allowed prompt diagnosis and treatment of an increasing number of menstrual disorders in an office setting. This White Paper reviews the advantages and disadvantages of transvaginal ultrasound, blind endometrial sampling and diagnostic hysteroscopy. Once a proper diagnosis has been established, appropriate therapy may be embarked upon...
August 7, 2017: Climacteric: the Journal of the International Menopause Society
https://www.readbyqxmd.com/read/28774663/fast-track-vs-delayed-insertion-of-the-levonorgestrel-releasing-intrauterine-system-after-early-medical-abortion-a-randomized-trial
#11
Riina Korjamo, Maarit Mentula, Oskari Heikinheimo
OBJECTIVE: To compare levonorgestrel (LNG) 52-mg intrauterine system (IUS) expulsion rates with fast track (≤ three days) or delayed (2-4weeks) insertion following mifepristone and misoprostol medical abortion. STUDY DESIGN: In this pilot trial we randomized 108 women≤63days gestation to fast-track (n=55) or delayed (n=53) insertion. Follow-up visits occurred at 2-4weeks, three months and one year. We assessed total and partial expulsion at three months and one year, adverse effects and bleeding profiles...
July 31, 2017: Contraception
https://www.readbyqxmd.com/read/28761925/recurrent-atypical-polypoid-adenomyoma-and-pregnancy-a-new-conservative-approach-with-levonorgestrel-releasing-intrauterine-system
#12
Eugenio Solima, Valeria Liprandi, Gaia M Belloni, Michele Vignali, Mauro Busacca
•Levonorgestrel IUD was effective in treatment of recurrent APA.•No side effects were reported.•No impairments on a subsequent pregnancy were reported.
August 2017: Gynecologic Oncology Reports
https://www.readbyqxmd.com/read/28754438/cost-effectiveness-of-treatments-for-heavy-menstrual%C3%A2-bleeding
#13
Jennifer C Spencer, Michelle Louie, Janelle K Moulder, Victoria Ellis, Lauren D Schiff, Tarek Toubia, Matthew T Siedhoff, Stephanie B Wheeler
BACKGROUND: Heavy menstrual bleeding affects up to one third of women in the United States, resulting in a reduced quality of life and significant cost to the health care system. Multiple treatment options exist, offering different potential for symptom control at highly variable initial costs, but the relative value of these treatment options is unknown. OBJECTIVE: The objective of the study was to evaluate the relative cost-effectiveness of 4 treatment options for heavy menstrual bleeding: hysterectomy, resectoscopic endometrial ablation, nonresectoscopic endometrial ablation, and the levonorgestrel-releasing intrauterine system...
July 25, 2017: American Journal of Obstetrics and Gynecology
https://www.readbyqxmd.com/read/28730844/correlation-between-uterine-artery-doppler-indices-and-menstrual-irregularities-among-levonorgestrel-releasing-intrauterine-system-and-depot-medroxyprogesterone-acetate-users-a-prospective-observational-study
#14
Mohamed Rezk, Alaa Al-Halaby, Mohamed Emarh, Mohamed Shawky
OBJECTIVE: To ascertain whether menstrual irregularities among users of levonorgestrel releasing intrauterine system (LNG-IUS) and depot medroxyprogesterone acetate (DMPA), were associated with changes in uterine artery Doppler indices or not. METHODS: This three-year prospective observational study included 102 women using LNG-IUS and 104 women using DMPA for contraception. Participants were followed at regular intervals over three years with performance of transvaginal ultrasound to measure uterine artery pulsatility index (PI) and resistance index (RI) before starting the method and at six months, 12 months, two and three years thereafter...
August 2017: European Journal of Contraception & Reproductive Health Care
https://www.readbyqxmd.com/read/28696796/lng-ius-12-a-19-5-levonorgestrel-releasing-intrauterine-system-for-prevention-of-pregnancy-for-up-to-five-years
#15
Anita L Nelson
Globally, intrauterine devices (IUDs) are the second most commonly used form of reversible contraception because of their high efficacy, safety, convenience and cost effectiveness. The levonorgestrel releasing intrauterine system with daily average release of 20 mcg (LNG-IUS 20) is the popular choice because of its favorable bleeding patterns and many noncontraceptive benefits. A three year (LNG-IUS 8) became available three years ago. More recently, the LNG-IUS 12 was added. This new IUD shares a smaller frame, narrow inserter and lower rate of amenorrhea with the LNG-IUS 8, but it offers the five years of contraceptive protection of the LNG-IUS 20...
August 2, 2017: Expert Opinion on Drug Delivery
https://www.readbyqxmd.com/read/28693985/cardiovascular-risk-markers-among-obese-women-using-the-levonorgestrel-releasing-intrauterine-system-a-randomised-controlled-trial
#16
Lucimara Facio Nobre Zueff, Anderson Sanches de Melo, Carolina S Vieira, Wellington P Martins, Rui A Ferriani
According to international guidelines, women with obesity without other comorbidities can safely use any hormonal contraceptive (HC). However, limited information is available about contraceptive safety for women with obesity since obesity is an exclusion criterion of most contraceptive clinical trials. As such little is known about the possible risks of HC exposure for women with obesity without comorbidities. One way to assess possible long-term risks in this population, even prior to the development of any clinical disease, is to measure alterations in subclinical atherosclerosis markers...
July 7, 2017: Obesity Research & Clinical Practice
https://www.readbyqxmd.com/read/28692170/expulsions-and-adverse-events-following-immediate-and-later-insertion-of-a-levonorgestrel-releasing-intrauterine-system-after-medical-termination-of-late-first-and-second-trimester-pregnancy-a-randomised-controlled-trial
#17
R Korjamo, M Mentula, O Heikinheimo
OBJECTIVES: To compare expulsions and adverse events (AEs) between immediate and delayed insertion of a levonorgestrel-releasing intrauterine system (LNG-IUS) following medical termination of pregnancy (MTOP). DESIGN: Randomised controlled trial. SETTING: Helsinki University Hospital, Finland, January 2013-December 2014. POPULATION: Cohorts of 102 (gestational age 64-84 days, late first trimester) and 57 (gestational age 85-140 days, second trimester) women requesting MTOP and LNG-IUS contraception...
July 10, 2017: BJOG: An International Journal of Obstetrics and Gynaecology
https://www.readbyqxmd.com/read/28683602/postoperative-levonorgestrel-releasing-intrauterine-system-insertion-after-gonadotropin-releasing-hormone-agonist-treatment-for-preventing-endometriotic-cyst-recurrence-a-prospective-observational-study
#18
Min Kyoung Kim, Seung Joo Chon, Jae Hoon Lee, Bo Hyon Yun, SiHyun Cho, Young Sik Choi, Byung Seok Lee, Seok Kyo Seo
OBJECTIVE: The aim of this study was to evaluate the effectiveness of postoperative levonorgestrel-releasing intrauterine system (LNG-IUS) insertion after gonadotropin-releasing hormone agonist (GnRH-a) treatment for preventing endometriotic cyst recurrence. STUDY DESIGN: The LNG-IUS was applied to 28 women who had undergone surgery for endometriosis followed by 6 cycles of GnRH-a treatment. Clinical characteristics, endometriosis recurrence, and adverse effects were analyzed...
January 1, 2017: Reproductive Sciences
https://www.readbyqxmd.com/read/28675069/clarification-of-the-role-of-the-jaydess-skyla-lng-ius-13-5mg-and-kyleena-lng-ius-19-5mg-as-intrauterine-contraceptive-systems
#19
Norman D Goldstuck
Jaydess/Skyla and Kyleena are 'low dose' levonorgestrel releasing intrauterine systems(LNG-IUS). They differ from Mirena and other similar LNG-IUSs in terms of pharmacological properties and physical dimensions. There are currently no defined guidelines to decide when to use Jaydess or Kyleena or Mirena. Areas covered: MEDLINE, POPLINE, PubMed and clinicaltrials.gov were searched using the terms 'Jaydess', 'Skyla', LNG-IUS 13.5mg and 'Kyleena' LNG-IUS 19.5mg. Only clinical research articles as opposed to generalised reviews and opinion papers on the newer LNG-IUSs were considered for review...
August 2017: Expert Review of Medical Devices
https://www.readbyqxmd.com/read/28650566/immediate-versus-delayed-initiation-of-the-levonorgestrel-releasing-intrauterine-system-following-medical-termination-of-pregnancy-1-year-continuation-rates-a-randomised-controlled-trial
#20
R Korjamo, M Mentula, O Heikinheimo
OBJECTIVE: To assess the 1-year continuation rates and new pregnancies following immediate versus delayed insertion of the levonorgestrel-releasing intrauterine system (LNG-IUS) after medical termination of pregnancy (MTOP) up to 20 weeks of gestation. DESIGN: A randomised controlled trial. SETTING: Helsinki University Hospital, Finland, January 2013 to December 2014. POPULATION: A total of 267 women requesting MTOP and planning LNG-IUS for post-MTOP contraception...
June 26, 2017: BJOG: An International Journal of Obstetrics and Gynaecology
keyword
keyword
70416
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"